This multicenter, phase I, open‐label study first demonstrated that pyrotinib, both alone and combined with docetaxel, was generally well tolerated and showed comparable antitumor activity in patients with HER2‐positive advanced GC. Here, ERBB2 is linked to gastric cancer.